Increased Levels of sCD30 Have No Impact on the Incidence of Early ABMR and Long-Term Outcome in Intermediate-Risk Renal Transplant Patients With Preformed DSA

URN to cite this document:: urn:nbn:de:bvb:355-epub-515345
DOI to cite this document:: 10.5283/epub.51534

Drasch, Thomas ; Bach, Christian ; Luber, Markus ; Spriewald, Bernd ; Utpatel, Kirsten

; Büttner-Herold, Maike ; Banas, Bernhard

; Zecher, Daniel

Preview

License: Creative Commons Attribution 4.0
PDF - Published Version
(770kB)

Date of publication of this fulltext: 27 Jan 2022 15:15

Alternative links to fulltext:DOI Publisher

Details

Preview

Export bibliographical data

Abstract

Background: It is still incompletely understood why some patients with preformed donor-specific anti-HLA antibodies (DSA) have reduced kidney allograft survival secondary to antibody-mediated rejection (ABMR), whereas many DSA-positive patients have favorable long-term outcomes. Elevated levels of soluble CD30 (sCD30) have emerged as a promising biomarker indicating deleterious T-cell help in ...